Pharmacokinetics of tepoxalin and its active metabolite in broiler chickens

Journal of Veterinary Pharmacology and Therapeutics

Volumn 32, Issue 1, 2009, Pages 97-100

  De Boever, S ^a   Neirinckx, E ^a   Baert, K ^a   De Backer, P ^a   Croubels, S ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; RWJ 20142; TEPOXALIN; UNCLASSIFIED DRUG; ZUBRIN;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CHICKEN; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHICKENS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; HALF-LIFE; INJECTIONS, INTRAVENOUS; PYRAZOLES; RANDOM ALLOCATION;

GALLUS GALLUS;

EID: 58449111816     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2008.01000.x     Document Type: Article

References (22)

1. Anonymous (2004) Draft Appendix A of the European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes (ETS No. 123). Guidelines for accommodation and care of animals (Article 5 of the Convention).
2. Anonymous (2005) Volume VIII, Notice to applicants, Veterinary medicinal products: Establishment of maximum residue limits (MRLs) for residues of veterinary products in foodstuffs of animal origin: Development and validation of a proposed regulatory method, EMEA/CVMP/573/00.
3. Argentieri, D.C., Ritchie, D.M., Ferro, M.P., Kirchner, T., Wachter, M.P., Anderson, D.W., Rosenthale, M.E. Capetola, R.J. (1994) Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favourable gastrointestinal profile. The Journal of Pharmacology and Experimental Therapeutics, 271, 1399 1408.
4. Baert, K., De Boever, S., Duchateau, L. De Backer, P. (2005a) Sodium salicylate attenuates lipopolysaccharide (LPS)-induced adipsia, but not hypophagia, in broiler chickens. British Poultry Science, 46, 144 148.
5. Baert, K., Duchateau, L., De Boever, S., Cherlet, M. De Backer, P. (2005b) Antipyretic effect of oral sodium salicylate after an intravenous E. coli LPS injection in broiler chickens. British Poultry Science, 46, 137 143.
6. De Boever, S., Beyaert, R., Vandemaele, F., Baert, K., Duchateau, L., Goddeeris, B., De Backer, P. Croubels, S. (2008) The influence of age and repeated lipopolysaccharide administration on body temperature and the concentration of interleukin-6 and IgM antibodies against lipopolysaccharide in broiler chickens. Avian Pathology, 37, 39 44.
7. EMEA (2003) Scientific discussion CVMP/221/01-Rev.3, 1 20.
8. 1-anti-chymotrypsin synthesis in astrocytes by preventing degradation of IκB-alpha. Neuropharmacology, 38, 1325 1333.
9. Homer, L.M., Clarke, C.R. Weingarten, A.J. (2005) Effect of dietary fat on oral bioavailability of tepoxalin in dogs. Journal of Veterinary Pharmacology and Therapeutics, 28, 287 291.
10. Kazmi, S.M., Plante, R.K., Visconti, V., Taylor, G.R., Zhou, L. Lau, C.Y. (1995) Suppression of NF kappa B activation and NF kappa B-dependent gene expression by tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase. Journal of Cellular Biochemistry, 57, 299 310.
11. Kirchner, T., Aparicio, B., Argentieri, D.C., Lau, C.Y. Ritchie, D.M. (1997) Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Prostaglandins, Leukotrienes and essential fatty acids, 56, 417 423.
12. Knight, E.V., Kimball, J.P., Keenan, C.M., Smith, I.L., Wong, F.A., Barrett, D.S., Dempster, A.M., Lieuallen, W.G., Panigrahi, W.J. Szot, R.J. (1996) Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and beagle dogs. Fundamental and Applied Toxicology, 33, 38 48.
13. Rainsford, K.D., Ying, C. Smith, F. (1993) Selective effects of some 5-lipoxygenase inhibitors on synovial interleukin-1 (IL-1) production compared with IL-1 synthesis inhibitors. Agents and Actions, 39, C186 C188.
14. Rainsford, K.D., Ying, C. Smith, F. (1996) Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture: comparison with interleukin-1-synthesis inhibitors. Journal of Pharmacy and Pharmacology, 48, 46 52.
15. Ritchie, D.M., Argentieri, D.C., Aparicio, B.L., Plante, R.K., Lau, C.Y. Barbone, A.G. (1995) Cytokine-modulating activity of tepoxalin, a new potential antirheumatic. International Journal of Immunopharmacology, 17, 805 812.
16. Schering-Plough Animal Health (2003) Zubrin. Technical Monograph, Schering-Plough Animal Health, Brussels.
17. Waldman, S.A., Vitow, C., Osborne, B., Gillen, L., Argentieri, D.C., Wong, F.A., Smith, I.L., Chow, A.T., Misiti, J. Bjornsson, T.D. (1996) Pharmacokinetics and pharmacodynamics of tepoxalin after single oral dose administration to healthy volunteers. Journal of Clinincal Pharmacology, 36, 462 468.
18. Wallace, J.L., Cirino, G., Cicala, C., Anderson, D.W., Argentieri, D. Capetola, R.J. (1991) Comparison of the ulcerogenic properties of tepoxalin with those of non-steroidal anti-inflammatory drugs (NSAIDs). Agents and actions, 34, 247 250.
19. Wallace, J.L., McCafferty, D., Carter, L. McKnight, W. (1993) Tissue-selective inhibition of prostaglandin synthesis in rat by tepoxalin: anti-inflammatory without gastropathy? Gastroenterology, 105, 1630 1636.
20. Willburger, R.E., Wittenberg, R.H., Schmidt, K., Kleemeyer, K.S. Peskar, B.A. (1998) Antiinflammatory effect of tepoxalin: blood and synovial tissue studied in patients with knee arthrosis. Acta Orthopedica Scandinavica, 69, 295 300.
21. Yamaoka, K., Nakagawa, T. Uno, T. (1978) Application of Akaike's information criteria (AIC) in the evaluation of linear pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics, 6, 165 175.
22. Zhou, L., Ritchie, D., Wang, E.Y., Barbone, A.G., Argentieri, D. Lau, C.Y. (1994) Tepoxalin, a novel immunosuppressive agent with a different mechanism of action from cyclosporin A. The Journal of Immunology, 153, 5026 5037.